Passage Bio, Inc. (PASG)
3.46
-0.05
(-1.42%)
USD |
NASDAQ |
Nov 05, 16:00
Passage Bio Enterprise Value : -13.02M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -13.02M |
| November 04, 2026 | -12.86M |
| November 03, 2026 | -13.21M |
| November 02, 2026 | -13.47M |
| October 30, 2026 | -13.05M |
| October 29, 2026 | -12.83M |
| October 28, 2026 | -13.44M |
| October 27, 2026 | -13.38M |
| October 26, 2026 | -13.35M |
| October 23, 2026 | -13.31M |
| October 22, 2026 | -12.86M |
| October 21, 2026 | -12.60M |
| October 20, 2026 | -12.57M |
| October 19, 2026 | -12.64M |
| October 16, 2026 | -12.89M |
| October 15, 2026 | -12.57M |
| October 14, 2026 | -12.38M |
| October 13, 2026 | -12.44M |
| October 12, 2026 | -9.514M |
| October 09, 2026 | -12.28M |
| October 08, 2026 | -11.99M |
| October 07, 2026 | -11.75M |
| October 06, 2026 | -11.03M |
| October 05, 2026 | -10.99M |
| October 02, 2026 | -10.90M |
| Date | Value |
|---|---|
| October 01, 2026 | -10.64M |
| September 30, 2026 | -9.675M |
| September 29, 2026 | -9.257M |
| September 28, 2026 | -9.112M |
| September 25, 2026 | -8.710M |
| September 24, 2026 | -8.710M |
| September 23, 2026 | -8.066M |
| September 22, 2026 | -8.227M |
| September 21, 2026 | -8.613M |
| September 18, 2026 | -8.870M |
| September 17, 2026 | -7.937M |
| September 16, 2026 | -8.516M |
| September 15, 2026 | -8.806M |
| September 14, 2026 | -8.516M |
| September 11, 2026 | -8.066M |
| September 10, 2026 | -8.114M |
| September 09, 2026 | -8.259M |
| September 08, 2026 | -8.549M |
| September 04, 2026 | -9.192M |
| September 03, 2026 | -8.870M |
| September 02, 2026 | -9.321M |
| September 01, 2026 | -9.868M |
| August 31, 2026 | -9.900M |
| August 28, 2026 | -9.610M |
| August 27, 2026 | -10.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.821M |
| Total Expenses (Quarterly) | 7.821M |
| EPS Diluted (Quarterly) | -2.437 |
| Earnings Yield | -326.9% |
| Normalized Earnings Yield | -320.89 |